Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Open-label Extension Study to Assess the Long-term Safety and Efficacy of Intravenous ATB200 Co-administered With Oral AT2221 in Adult Subjects With Late-onset Pompe Disease (LOPD)

NCT04138277 is registered in ClinicalTrials.gov with Amicus Therapeutics as lead sponsor.

NCT NCT04138277
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04138277 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Open-label Extension Study to Assess the Long-term Safety and Efficacy of Intravenous ATB200 Co-administered With Oral AT2221 in Adult Subjects With Late-onset Pompe Disease (LOPD)
Lead sponsor
Amicus Therapeutics
Phase
Phase 3
Overall status
Completed
Start date
December 18, 2019
Completion date
December 31, 2024
Enrollment
119 (actual)
Sites
60

Conditions

As the registry lists them; a condition with its own page is linked.

pompe disease (late-onset)